Checkpoint Therapeutics

Company profile

About

Checkpoint Therapeutics (NASDAQ:CKPT) is a biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company is dedicated to advancing a diverse portfolio of immuno-oncology and targeted cancer therapies aiming to address the unmet medical needs of patients. With a strategic approach to drug development, Checkpoint Therapeutics is actively working on bringing innovative cancer treatments through clinical trials with the ultimate goal of improving patient outcomes. Their projects span from early to late-stage clinical trials, focusing on key areas such as non-small cell lung cancer and cutaneous T-cell lymphoma. The objective of Checkpoint Therapeutics is to leverage its expertise to develop and commercialize life-enhancing cancer treatments globally.

Snapshot

2014Year founded

23Employees

Waltham, United StatesHead office

Loading Map...

Global footprint

Operations

All Locations

Waltham, US

Products and/or services of Checkpoint Therapeutics

Cosibelimab, a monoclonal antibody targeting PD-L1 for treating metastatic cutaneous squamous cell carcinoma.
Olafertinib, an EGFR mutation inhibitor aimed at non-small cell lung cancer with specific genetic alterations.
CK-101, a third-generation EGFR inhibitor for lung cancer patients resistant to first-line treatments.
CK-103, a BET inhibitor designed for the treatment of solid tumors and hematologic malignancies.
CK-302, an anti-GITR monoclonal antibody in development for various advanced cancers.
CK-303, a novel antibody-drug conjugate targeting cancer cells with minimal impact on healthy tissue.